Processing

Please wait...

Settings

Settings

Goto Application

1. WO2002000692 - PD-L2 MOLECULES: PD-1 LIGANDS AND USES THEREFOR

Publication Number WO/2002/000692
Publication Date 03.01.2002
International Application No. PCT/US2001/020858
International Filing Date 28.06.2001
Chapter 2 Demand Filed 17.01.2002
IPC
G01N 33/50 2006.1
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
G01N 33/573 2006.1
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
573for enzymes or isoenzymes
G01N 33/68 2006.1
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
68involving proteins, peptides or amino acids
CPC
A61P 11/06
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
11Drugs for disorders of the respiratory system
06Antiasthmatics
A61P 29/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
29Non-central analgesic, antipyretic or anti-inflammatory agents, e.g antirheumatic agents; Non-steroidal anti-inflammatory drugs (NSAIDs)
A61P 3/10
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
3Drugs for disorders of the metabolism
08for glucose homeostasis
10for hyperglycaemia, e.g. antidiabetics
A61P 31/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
31Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
A61P 35/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
A61P 37/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
37Drugs for immunological or allergic disorders
Applicants
  • GENETICS INSTITUTE, LLC. [US]/[US]
  • DANA-FARBER CANCER INSTITUTE, INC. [US]/[US]
  • BRIGHAM AND WOMEN'S HOSPITAL [US]/[US]
Inventors
  • FREEMAN, Gordon
  • CHERNOVA, Irene
  • CHERNOVA, Tatyana
  • MALENKOVICH, Nelly
  • WOOD, Clive
  • LATCHMAN, Yvette
  • SHARPE, Arlene, H.
Agents
  • MANDRAGOURAS, Amy, E.
Priority Data
60/214,56328.06.2000US
60/270,82223.02.2001US
60/271,11423.02.2001US
Publication Language English (en)
Filing Language English (EN)
Designated States
Title
(EN) PD-L2 MOLECULES: PD-1 LIGANDS AND USES THEREFOR
(FR) MOLECULES PD-L2: NOUVEAUX LIGANDS POUR PD-1 ET LEURS UTILISATIONS
Abstract
(EN) The invention provides isolated nucleic acid molecules, designated PD-L2 nucleic acid molecules, which encode novel B7-related molecules which are ligands for PD-1. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing PD-L2 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a PD-L2 gene has been introduced or disrupted. The invention further provides isolated PD-L2 polypeptides, fusion proteins, antigenic peptides and anti-PD-L2 antibodies. The invention still further provides methods for promoting or inhibiting the interaction between PD-L2 and PD-1. Diagnostic and treatment methods utilizing compositions of the invention are also provided.
(FR) L'invention concerne des molécules d'acide nucléique isolées, appelées molécules d'acide nucléique PD-L2, qui codent pour de nouvelles molécules liées à B7 qui sont des ligands pour PD-1. L'invention concerne également des molécules d'acide nucléique antisens, des vecteurs d'expression de recombinaison contenant des molécules d'acide nucléique PD-L2, des cellules hôtes dans lesquelles les vecteurs d'expression ont été introduits, et des animaux transgéniques non humains dans lesquels un gène PD-L2 a été introduit ou disloqué. L'invention concerne en outre des polypeptides isolés PD-L2, des protéines de fusion, des peptides antigéniques et des anticorps anti-PD-L2. L'invention concerne également des méthodes permettant de stimuler ou d'inhiber l'interaction entre PD-L2 et PD-1. L'invention concerne enfin des méthodes de diagnostic et de traitement utilisant les compositions selon l'invention.
Latest bibliographic data on file with the International Bureau